Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | MET | P08581 | 7/20 | 0.47 |
| ▸ | AXL | P30530 | 3/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | MST1R | Q04912 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729998 | 0.92 | KDR (1.00) | KDRMETAXLMERTKBRAF | |
| SCHEMBL4729055 | 0.89 | KDR (0.84) | KDRMETAXLMERTKBRAF | |
| SCHEMBL4337595 | 0.87 | KDR (0.76) | KDRMETAXLMERTKBRAF | |
| SCHEMBL4922078 | 0.86 | KDR (0.76) | KDRMETAXLMERTKBRAF | |
| SCHEMBL13860941 | 0.82 | KDR (0.70) | KDRMETAXLMERTKBRAF | |
| SCHEMBL4322741 | 0.81 | KDR (0.69) | KDRMETAXLMERTKBRAF | |
| SCHEMBL4733536 | 0.81 | KDR (0.69) | KDRAXLMERTKBRAFRAF1 | |
| SCHEMBL4888435 | 0.79 | KDR (0.67) | KDRAXLMERTKBRAFRAF1 | |
| SCHEMBL4343712 | 0.79 | KDR (0.66) | KDRMETAXLMERTKBRAF | |
| SCHEMBL13861144 | 0.79 | KDR (0.65) | KDRMETAXLMERTKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | KDR 746/4885MET 545/4885AXL 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.